Skip to main content
logo
Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price on Jan 5, 2026

Mersana Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-70.08-69.19-171.67-204.21-170.06-88.05
Depreciation & Amortization
1.091.631.520.930.861.01
Stock-Based Compensation
9.2616.4621.1421.5218.417.17
Other Adjustments
3.58-0.5-1.12.082.550.06
Change in Receivables
--30-30--
Changes in Accounts Payable
0.36-2.86-6.080.950.480.94
Changes in Accrued Expenses
-3.81-2.93-20.9413.5912.577.28
Changes in Unearned Revenue
-12.51-23.88-22.14143.71-0.04-0.83
Changes in Other Operating Activities
-2.32-1.070.392.07-4.75-2.29
Operating Cash Flow
-74.37-82.34-168.88-49.36-139.99-74.7
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Capital Expenditures
--0.13-2.17-2.2-0.65-0.47
Purchases of Investments
--133.43-155.92-247.52--
Proceeds from Sale of Investments
-145277.9797-37.5
Investing Cash Flow
77.7711.44119.88-152.72-0.6537.03

Financing Activities

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Long-Term Debt Issued
---0.15-24.04-
Long-Term Debt Repaid
-26.06-2.08---5.49-0.2
Net Long-Term Debt Issued (Repaid)
-26.06-2.08-0.15-18.56-0.2
Issuance of Common Stock
-6.3295.09153.2945.56230.73
Net Common Stock Issued (Repurchased)
-6.3295.09153.2945.56230.73
Other Financing Activities
-0.07-0.15-0.26-0.27-0.47-0.12
Financing Cash Flow
-25.874.0994.68153.0263.65230.41

Net Cash Flow

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Cash Flow
-22.48-66.8145.68-49.06-76.99192.74
Beginning Cash & Cash Equivalents
79.35175.04129.36178.43255.4262.67
Ending Cash & Cash Equivalents
56.87108.23175.04129.36178.43255.42

Free Cash Flow

Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Free Cash Flow
-74.37-82.47-171.05-51.56-140.64-75.17
Free Cash Flow Growth
------
FCF Margin
-224.14%-203.65%-464.12%-193.97%-327060.47%-9078.38%
Free Cash Flow Per Share
-14.95-16.83-36.83-13.76-49.81-30.56
Levered Free Cash Flow
-113.34-100.52-221.23-45.16-143.04-82.6
Unlevered Free Cash Flow
-84.58-102.13-229.08-44.72-160.4-82.47
SEC Filings: 10-K · 10-Q